ArticleBMC cancer2024
Patterns of breast cancer locoregional relapse, metastasis, and subtypes in Ghana.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breast Cancer Care in Ghana: A Review of the Continuum of Care and Progress Toward Universal Health Coverage.International journal of breast cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSignificant advances have been made in targeted therapeutics and systemic therapy regimens for breast cancer (BC) treatment over the past decade. Tumour cells can however remain in the body, leading to locoregional relapse and/or metastasis. Subtypes of BC have distinct prognostic effects and have been linked to varying risks of early locoregional relapse and metastases, response to treatment, and overall survival. Most Low- and middle-income countries (LMICs) have no registries of BC locoregional relapse and metastasis.
methodsThis study comprehensively reviewed, a 3-year retrospective single-centre data of female BC visiting the Komfo Anokye Teaching Hospital (KATH), Ghana to determine the prevalence of locoregional relapse and metastasis across our patient population. Prevalence of metastasis among the various BC subtypes was also determined.
resultsPrevalence of BC locoregional relapse and metastasis were 3.4% and 47.6% respectively. For BC patients with documented locoregional relapse (N = 36), 27.8% (CI = 15.8 - 44.0%) had relapse to the contralateral breast, 41.7% (CI = 27.1 - 57.8%) had relapse to the ipsilateral breast, and 30.6% (CI = 18.0 - 46.9%) had relapse to regional lymph nodes. For BC patients with documented metastasis (N = 503), 151 (30%) had multiple organs involvement, 141 (28%) had lung metastases, 80 (16%) had bone metastases, 45 (9%) had liver metastases, 16 (3%) had brain metastases and 70 (14%) had other metastases (ovary, uterus, spleen, peritoneum, or distant lymph nodes). Basal subtype was the most common subtype (n = 82, 41%), followed by Luminal A (n = 69, 34.5%), HER2+ (n = 37, 18.5%) and Luminal B (n = 12, 6%). Basal subtypes had the most metastasis (35%), with multiple metastasis being the most prevalent (13%).
conclusionClose to half of the patients (46%) presented with metastatic BC. BC subtypes could influence the specific metastatic site. The most common BC subtype was the Basal subtype and had the most metastases (35%), with multiple metastasis being the most prevalent (13%). These findings should serve as a guide in the management of patients to enhance early prediction and detection of locoregional relapse and metastasis for improved overall treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.